Iltoo Pharma

Executive Summary

Iltoo Pharma is a French biotechnology company founded in 2013 that is pioneering regulatory T cell (Treg)-directed therapies to treat autoimmune, neuroimmune, and inflammatory diseases. The company's initial focus is Amyotrophic Lateral Sclerosis (ALS), a devastating neurodegenerative disease with high unmet need. Iltoo leverages a proprietary platform to expand and modulate Treg cells, aiming to restore immune tolerance and halt disease progression. The company benefits from strong academic and industrial partnerships, positioning it as an innovative player in the Treg therapy space. While Iltoo is private and has disclosed limited financial information, its approach holds promise given the growing interest in cell-based immunotherapies for autoimmune conditions. However, the early-stage nature of its programs and absence of clinical data in the public domain mean that substantial execution and regulatory risks remain.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 1/2 clinical trial for ILT-101 in ALS35% success
• Q3 2026Announcement of new partnership or grant funding60% success
• Q4 2026Preclinical data publication for second indication (e.g., multiple sclerosis)50% success